Ark Therapeutics Group plc announced today that
its novel gene-based drug targeting platform technology, Scavidin(R) has been
shown to be highly effective in stopping tumour development in two cancer
treatment models, using low doses of existing anti-cancer agents which would be
sub-therapeutic if administered conventionally. Scavidin(R) was used to target
and concentrate intravenous doses of as little as one-tenth the conventional
levels of the radioisotope Yttrium(90) in one model, and the chemotherapy drug
paclitaxel in another, to tumours growing under the skin. The results indicate
a wide utility for this leading edge technology in very large markets.
